Of the 950 included GC patients in the three cohorts, 288 had a HER2-p status (244 had an IHC analysis score of 3+ , and 44 had an IHC analysis score of 2+ plus positive findings on FISH), and the remaining 662 had a HER2-n (620 had an IHC analysis score of 0/1+ and 42 had an IHC analysis score of 2+ plus negative findings on FISH). The gene discussed is ERBB2; the disease is gastric cancer.